Swiss Pharma Company – IDEOGEN takes over the special access program for BELEODAQ® (belinostat)

HURDEN, Switzerland, January 21, 2022 /PRNewswire/ — IDEOGEN GROUP, Managed Access Division Supports Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russiaand IEC.

BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that has relapsed or is not responding to previous treatment. PTCL is a group of rare and aggressive non-Hodgkin’s lymphoma (NHL), a malignant lymphoproliferative disorder. PTCL accounts for about 10% to 15% of all NHL cases.

BELEODAQ® (belinostat) is the only histone deacetylase inhibitor (“HDAC inhibitor”) globally for the treatment of refractory/relapsed PTCL. The product has received accelerated approval from the United States Food and Drug Administration (“FDA”) due to the high unmet medical need for this rare disease.

Murat Goker, The Chief Commercial Officer of Ideogen Group, said: “Our modus operandi is to meet patients’ unmet medical needs at the speed of life. As a trusted partner, we provide access for patients around the world affected by underserved diseases. Our special access programs allow physicians access to drugs like BELEODAQ® (belinostat) for each patient’s unique circumstances when alternative treatment options are needed.

“We are privileged to be the exclusive fulfillment partner representing BELEODAQ® for immediate availability in many territories*. Due to the time-sensitive disease state of the patient with relapsed/refractory PTL, BELEODAQ® is stocked in the EU and available for delivery to any ordering pharmacist or doctor on the continent Europe with rapid deployment,” says Mehmet GokerOperations Manager.

Healthcare professionals can get details about BELEODAQ® Special Access Program by calling an Ideogen representative at +800 22 44 77 00 or emailing [email protected].

About IDEOGEN: We are focused on bringing specialty medicines to market with an exciting and scalable healthcare dynamic. With the operational infrastructure and know-how to manage the business from unlicensed to licensed drugs, Ideogen maintains a strong network of professionals and caregivers, nurturing strong medical alliances for the benefit of patients.

Our portfolio focuses on medicines that require expertise in solving challenging regulatory, market access, quality, PV and execution requirements for specialty disease segments. From initial inquiry to on-time delivery, we are available 24/7 worldwide.

For more information, also visit www.ideogen.com

*Exclusive coverage of territories: Albania , Algeria, Armenia, Austria, Bahrain, Belgium, bosnia, Bulgaria, Croatia, Cyprus, Czech Republic , Denmark, Djibouti, Egypt, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Iran, Iraq, Ireland, Israel, Italy, Jordan, KazakhstanKyrgyzstan, Kuwait, Latvia, Lebanon, Libya, Liechtenstein, Lithuania, Luxemburg, fruit salad, Malta, Moldova, monaco, Montenegro, Morocco, Netherlands, Norway, OmanPalestine, Poland, Portugal, Qatar, Romania, Russia, Saudi ArabiaSerbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Syria, Turkey, Tunisia, UkraineUK, UzbekistanUnited Arab Emirates and Yemen

Logo: https://mma.prnewswire.com/media/1730926/Ideogen_Logo.jpg

For media relations, please contact: [email protected]; [email protected]; phone: +41 43 311 5252

SOURCE IDEOGEN AG

Comments are closed.